RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
多形性胶质母细胞瘤的免疫治疗策略：机制与临床应用
英文原题：Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.
查看英文原题
Immunotherapeutic Approaches for the Treatment of Glioblastoma Multiforme: Mechanism and Clinical Applications.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
胶质瘤是最具侵袭性的原发性脑肿瘤之一，其中高级别胶质瘤被称为多形性胶质母细胞瘤（GBM）。诊断为GBM的患者在接受常规治疗后，总生存率通常低于18个月。这种黯淡的预后凸显了考虑新的治疗干预措施以克服当前治疗局限性的必要性。通过重点介绍目前处于临床前和临床试验中的不同免疫治疗方法，包括免疫检查点抑制剂、CAR-T 细胞、NK 细胞、疫苗和联合治疗，本综述旨在讨论免疫治疗在治疗GBM患者中的机制、益处和局限性。
展开英文摘要原文
Glioma is one of the most aggressive types of primary brain tumor with a high-grade glioma known as glioblastoma multiforme (GBM). Patients diagnosed with GBM usually have an overall survival rate of less than 18 months after conventional therapy. This bleak prognosis underlines the need to consider new therapeutic interventions for GBM treatment to overcome current treatment limitations.
By highlighting different immunotherapeutic approaches currently in preclinical and clinical trials, including immune checkpoint inhibitors, chimeric antigen receptors T cells, natural killer cells, vaccines, and combination therapy, this review aims to discuss the mechanisms, benefits, and limitations of immunotherapy in treating GBM patients.
论文信息
- 作者
- Das S、Dash BS、Premji TP、Chen JP
- 单位
- Department of Chemical and Materials Engineering, Chang Gung University, Kwei-San, Taoyuan 33302, Taiwan.Taiwan
- 文献类型
- 综述
- 期刊
- International journal of molecular sciences2023 Jun 23
- 原文标识
- PubMed 37445721 · DOI 10.3390/ijms241310546
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →